Altimmune, Inc. (ALT)
3.155
-0.04
(-1.41%)
USD |
NASDAQ |
Aug 26, 16:00
3.16
0.00 (0.00%)
After-Hours: 20:00
Altimmune Debt to Equity Ratio : 0.076 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.076 |
| March 31, 2026 | 0.1262 |
| December 31, 2025 | 0.1587 |
| September 30, 2025 | 0.0857 |
| June 30, 2025 | 0.0982 |
| March 31, 2025 | 0.0112 |
| December 31, 2024 | 0.0136 |
| September 30, 2024 | 0.0133 |
| June 30, 2024 | 0.0122 |
| March 31, 2024 | 0.0032 |
| December 31, 2023 | 0.0035 |
| September 30, 2023 | 0.0052 |
| June 30, 2023 | 0.0054 |
| March 31, 2023 | 0.0061 |
| December 31, 2022 | 0.0061 |
| September 30, 2022 | 0.006 |
| June 30, 2022 | 0.0069 |
| March 31, 2022 | 0.0078 |
| December 31, 2021 | 0.0077 |
| September 30, 2021 | 0.0078 |
| June 30, 2021 | 0.0068 |
| March 31, 2021 | 0.0071 |
| December 31, 2020 | 0.0081 |
| September 30, 2020 | 0.0095 |
| June 30, 2020 | 0.0283 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0402 |
| December 31, 2019 | 0.0383 |
| September 30, 2019 | 0.0387 |
| June 30, 2019 | 0.0406 |
| March 31, 2019 | 0.0419 |
| December 31, 2018 | 0.0119 |
| September 30, 2018 | 0.0507 |
| June 30, 2018 | 0.0522 |
| March 31, 2018 | 0.0143 |
| December 31, 2017 | 0.001 |
| September 30, 2017 | 0.0112 |
| June 30, 2017 | 0.0082 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.0142 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.013 |
| June 30, 2015 | 0.0136 |
| March 31, 2015 | 0.0249 |
| December 31, 2014 | 0.0408 |
| September 30, 2014 | 0.0549 |
| June 30, 2014 | 0.1799 |
| March 31, 2014 | 0.1784 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Amgen, Inc. | 4.903 |
| Protalix Biotherapeutics, Inc. | 0.1289 |
| Taysha Gene Therapies, Inc. | 0.1469 |
| Humacyte, Inc. | 2.117 |
| Liquidia Corp. | 0.9374 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 527.21M |
| Total Liabilities (Quarterly) | 53.00M |
| Shareholders Equity (Quarterly) | 474.21M |
| Current Ratio | 26.77 |
| Net Debt Paydown Yield | -1.16% |